RT Book, Section
A1 Rodwell, Victor W.
A2 Rodwell, Victor W.
A2 Bender, David A.
A2 Botham, Kathleen M.
A2 Kennelly, Peter J.
A2 Weil, P. Anthony
SR Print(0)
ID 1160190604
T1 Metabolism of Purine & Pyrimidine Nucleotides
T2 Harper's Illustrated Biochemistry, 31e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781259837937
LK accessmedicine.mhmedical.com/content.aspx?aid=1160190604
RD 2024/04/20
AB OBJECTIVESAfter  studying  this  chapter,  you  should  be  able  to:Compare  and  contrast  the  roles  of  dietary  nucleic  acids  and  of  de  novo  biosynthesis  in  the  production  of  purines  and  pyrimidines  destined  for  polynucleotide  biosynthesis.Explain  why  antifolate  drugs  and  analogs  of  the  amino  acid  glutamine  inhibit  purine  biosynthesis.Outline  the  sequence  of  reactions  that  convert  inosine  monophosphate  (IMP),  first  to  AMP  and  GMP,  and  subsequently  to  their  corresponding  nucleoside  triphosphates.Describe  the  formation  from  ribonucleotides  of  deoxyribonucleotides  (dNTPs).Indicate  the  regulatory  role  of  phosphoribosyl  pyrophosphate  (PRPP)  in  hepatic  purine  biosynthesis  and  the  specific  reaction  of  hepatic  purine  biosynthesis  that  is  feedback  inhibited  by  AMP  and  GMP.State  the  relevance  of  coordinated  control  of  purine  and  pyrimidine  nucleotide  biosynthesis.Identify  the  reactions  discussed  that  are  inhibited  by  anticancer  drugs.Write  the  structure  of  the  end  product  of  purine  catabolism.  Comment  on  its  solubility  and  indicate  its  role  in  gout,  Lesch-Nyhan  syndrome,  and  von  Gierke  disease.Identify  reactions  whose  impairment  leads  to  modified  pathologic  signs  and  symptoms.Indicate  why  there  are  few  clinically  significant  disorders  of  pyrimidine  catabolism.